A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
Ikena Oncology
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC